Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma

Fig. 2

Effect of vanoxerine dihydrochloride treatment on cell cycle distribution in QGY7703 and Huh7 cells. a QGY7703 and b Huh7 cells were treated with different concentrations (3, 10 and 30 μM) of vanoxerine dihydrochloride for 6, 12, 24 hours. Cell cycle distributions were measured by flow cytometry. Vanoxerine dihydrochloride dose- and time-dependently increased the % of cells in G1 phase, as compared to PBS control. b The cell cycle distributions at 24 h after 10 μM vanoxerine dihydrochloride treatment. The bar graph indicated the percentage of the G1, S and G2-M phases. *p < 0.05, significantly different from the control PBS treatment group

Back to article page

Molecular Medicine

ISSN: 1528-3658